SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Taro Pharmaceutical Industries Ltd. TARO NYSE

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic • IL • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Taro Pharmaceutical Industries Ltd. (TARO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $42.98. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $629M, +4.7%/yr average growth. Net income is $54M, growing at +56.6%/yr. Net profit margin is 8.6% (thin). Gross margin is 48.5% (-5.5 pp trend).

Balance sheet: total debt is $0 against $1.8B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 3.61 (strong liquidity). Debt-to-assets is 0%. Total assets: $2.2B.

Analyst outlook: 1 / 2 analysts rate TARO as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 73/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 48/100 (Partial), Future 40/100 (Partial), Income 45/100 (Partial).

TARO SharesGrow Score Overview

63/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 60/100

Valuation — P/E, PEG, Forward PEG

GROWTH 73/100

Financials — average growth

PAST 75/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 48/100

Gross margin is + market cap

FUTURE 40/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TARO

TARO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

TARO: +4.7%/yr revenue is, +56.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

TARO: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet TARO: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 3.61 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

TARO: Gross margin is 48.5% (-5.5 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 48/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 2 analysts rate TARO as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

TARO: Net profit margin is 8.6%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range32.67-45.76

Volume147.06K

Avg Volume (30D)32.93K

Market Cap$1.62B

Beta (1Y)0.56

Share Statistics

EPS (TTM)1.43

Shares Outstanding$37.58M

IPO Date1982-09-14

Employees1,554

CEOUday V. Baldota

Financial Highlights & Ratios

Revenue (TTM)$629.18M

Gross Profit$304.98M

EBITDA$38.4M

Net Income$53.87M

Operating Income$21.51M

Total Cash$879.35M

Net Debt$-362.91M

Total Assets$2.16B

Price / Earnings (P/E)30.1

Price / Sales (P/S)2.57

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 50% Hold 50% Sell 0%

Company Info

CountryIL

ExchangeNYSE

CurrencyUSD

ISINIL0010827181

Price Chart

TARO

Taro Pharmaceutical Industries Ltd. ↗ · NYSE

Healthcare • Drug Manufacturers - Specialty & Generic

32.67 52WK RANGE 45.76

People Also View

Dr. Reddy's Laboratories Limited

Supernus Pharmaceuticals, Inc.

Prestige Consumer Healthcare Inc.

Phibro Animal Health Corporation

Deciphera Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

Collegium Pharmaceutical, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message